IBM and Boehringer Ingelheim Partner on Generative AI for Transformative Antibody Therapeutics
What You Should Know:
– Boehringer Ingelheim and IBM announced a collaboration to leverage IBM’s foundation model technologies for the discovery of novel candidate antibodies in drug development.
– The partnership will focus on utilizing IBM’s…
Continue Reading